Sofinnova Investments, Inc. Travere Therapeutics, Inc. Transaction History

Sofinnova Investments, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$17.82 - $22.89 $12.2 Million - $15.7 Million	685,453 Added 118.54%	1,263,721 $28.4 Million
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $3.39 Million - $4.8 Million	183,590 Added 46.52%	578,268 $12.2 Million
Q3 2022 Nov 08, 2022	BUY	$22.91 - $28.63 $4.17 Million - $5.21 Million	182,085 Added 85.65%	394,678 $9.73 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $9.33 Million - $13.4 Million	-445,656 Reduced 67.7%	212,593 $5.15 Million
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $9.03 Million - $11.7 Million	-382,609 Reduced 36.76%	658,249 $17 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $14.7 Million - $18.8 Million	603,578 Added 138.03%	1,040,858 $32.3 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $5.68 Million - $10.9 Million	437,280 New	437,280 $10.6 Million

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.